BIO — Bio Rad Laboratories Cashflow Statement
0.000.00%
- $6.80bn
- $6.33bn
- $2.57bn
- 91
- 61
- 49
- 75
Annual cashflow statement for Bio Rad Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 18.1 | 47.8 | 85.8 | 108 | 106 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | 585 | 669 | 194 | 375 | 455 |
Capital Expenditures | -109 | -134 | -113 | -157 | -189 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 38.7 | -664 | -1,095 | 177 | 28.8 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Cash from Investing Activities | -69.9 | -797 | -1,208 | 20.2 | -160 |
Financing Cash Flow Items | -16.3 | -23 | -14 | -14.9 | -34 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -523 | -55.4 | 974 | -426 | -219 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 4.46 | -196 | -36.6 | -30.2 | 85.4 |